SG Americas Securities LLC Takes $192,000 Position in Savara Inc (NASDAQ:SVRA)

SG Americas Securities LLC acquired a new stake in shares of Savara Inc (NASDAQ:SVRA) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 45,259 shares of the company’s stock, valued at approximately $192,000.

A number of other hedge funds also recently bought and sold shares of SVRA. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Savara during the 2nd quarter worth approximately $215,000. Nantahala Capital Management LLC boosted its stake in Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after buying an additional 3,443,541 shares during the last quarter. Algert Global LLC boosted its stake in Savara by 21.0% during the second quarter. Algert Global LLC now owns 238,807 shares of the company’s stock worth $962,000 after buying an additional 41,377 shares during the last quarter. Frazier Life Sciences Management L.P. grew its holdings in Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after buying an additional 4,157,385 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC increased its stake in shares of Savara by 46.5% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 115,831 shares of the company’s stock worth $467,000 after acquiring an additional 36,758 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

Savara stock opened at $3.41 on Thursday. The company’s 50 day simple moving average is $4.14 and its 200-day simple moving average is $4.33. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. Savara Inc has a 1 year low of $3.12 and a 1 year high of $5.70. The company has a market capitalization of $471.22 million, a price-to-earnings ratio of -9.22 and a beta of 0.96.

Savara (NASDAQ:SVRA) last posted its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). As a group, equities research analysts expect that Savara Inc will post -0.44 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Oppenheimer upped their price objective on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, June 26th. JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. Guggenheim lifted their price target on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Savara in a research report on Tuesday, October 8th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Savara presently has an average rating of “Buy” and an average target price of $11.17.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.